Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
yeah. i still will try and get some on monday.
had my buy in at 1.70 and no such luck. not happy.
who's going to play this
superstockhunter just sent out an email promoting SEFE as their pick of the year.
Would have loved to get in 2 months ago in the .30s
Good stuff. I found the email. Aol thought it was spam. I am good to go now.
Haha. I think i still pay a monthly fee. Just joking.
No an aol account. Don't laugh. lol
I didn't receive the email. I have signed up twice.
Is it worth getting back in? Do you think it will get back to its highs?
As Ghost would say "Tru Dat." I did make a good chunk and am looking for more.
New to the game but have been following you guys on the snpk site before you started APS. I appreciate the honest opinions and the semi conservative approach. I was killing myself for getting out at 1.48, but after reading several of your posts, I understand. Any day is a good day when you take profits!!
I am looking forward to playing the next one with you guys/gals. I enjoy it so much I upped by ihub account so I can post :)
Thanks!!
Just did. Definitely looking forward to making some $$$$$
Would love to see APS put out a new stock while SNPK is booming. Just a thought...
Just sold for a nice gain. Been in since .65. I couldn't take the pressure anymore. lol. I hope SNPK proves me wrong. Good Luck to all!!
1.69
Check. Thanks again!!
Sweet. Will be following the board...
Garyst,
Thanks for your insight. Usually you say if you think it's going to drop or not and that you will be watching closely but not selling unless something drastic happens.
Tonight you said you will be watching closely, but do you think we will see a big drop? I understand it's just your opinion, but curious to see what you think. I won't hold you to it :)
Thanks!!
$1.77 close
Closing price of 1.37
Thanks!!! That explains it all.
I was going to post that I totally understand the housing market, since I live in South Florida (lol), but you would think with all these natural disasters happening in the U.S. we would want to build our homes safer and stronger.
Your highlighted sentence explains everything. Hopefully, the building industry will wake up!!!
With all the Natural Disasters (Tornadoes, etc...) taking place in the United States, I really don't know how this company is not getting any contracts for their houses, especially trailer homes. If I remember correctly, the company has said that the homes can withstand cat 5 hurricane winds or something like that and the prices are only slightly more expensive. Really doesn't make sense if this is a legitimate company.
I am long and strong.
I don't see an email from APS.
impressive... i was wondering if MC Endeavors was trying to educate the states/cities/counties that got devastated by the recent tornadoes.
post it...
Too bad AwesomePennyStocks doesn't promote this stock. Anybody have anything good to say about this stock?
We need to get the word out.
News from Pennystockshark.com. I can't believe nobody has posted.
As we mentioned last night, There isn't a day that goes by on Wall Street when some stocks trading near or under $1 a share don't experience massive spikes higher. Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis. Check out Emo Capital Corporation.(NUVI:OTC) now, we see very little resistance at this price level (.71), & NUVI is trading on average of 250,000 shares a day!
NanoViricides, Inc
Symbol: NUVI
Current Price: $.73
52 Week Range: $.02 -.82
www.nuvitalitylabs.com/
http://finance.yahoo.com/q?s=NUVI.OB&ql=1
NUVI:OTC Look at this trend!
Want a immediate reason to put NUVI on your radar?
Simple Moving Average (SMA)
Yesterday, NUVI closed above its 10 day moving average. This is generally considered to be an indication of a bullish trend.
About NUVI-
"We are an international direct selling company that has passionately created products and resources that has helped millions of people pursue their paths to a healthy, active lifestyle. Our nutrition, weight-management and personal care products are available exclusively through our agent and distributor channels and are available across North America and many international countries.
Everyday scientific advances are made to help you live longer and help you live better. We develop products that benefit from some of the most technologically advanced ingredients available today. Beyond our commitment to advanced products and industry knowledge, Nu Vitality Labs is committed to making the world a better place for children through our Nu Vitality Labs "Helping Hands" Foundation. We do what we do because we think it's essential to do our small part as part of the movement to make people and the planet healthier. In doing so, we believe each of our contributions put together will create the major change we wish to see in the world."
Our Vision
"The caliber of our products and the simplicity of our business plan means anyone can improve their quality of life. Some begin as customers in search of better health products, and they can't help but share their great product experiences. Others see the business potential immediately and start a successful home-based business.
With millions of people just like you who have the same goals in life, better health and financial freedom, Nu Vitality Labs is successful because it values what you value. It gives you the tools to take control and live the life you've always wanted."
It's one of the most active stocks of the week, and things are now heating up with the latest news release. NUVI's on a quest to become a household name in the almost $800 million dollar diet and wellness industry in Australia. That's right, NUVI's new market is HUGE.If you are looking for a stock with big upside potential in the short-term, NUVI might be just what you are looking for!
Trade Well, and remember to take profits when you can!
PennyStockShark.com
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE unless you can afford to lose your entire investment. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. PennyStockShark.com is a wholly owned subsidiary of Raven Consulting Corp. Raven Consulting Corp. has been compensated up to $25,000 for this NUVI advertising and promotion by Equities Awareness Group, a third party. All direct third party compensation received will be fully disclosed in any communication regarding a profiled company. This website is a service of Raven Consulting,, Corp, a financial public relations firm that has been compensated by the companies profiled. All direct and third party compensation received has been disclo sed within each individual profile in accordance with section 17(b) of the Securities A c t of 1 9 3 3. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. Raven Consulting Corp, and/or its affiliated will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materi als we produce at any time. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer t o buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them. Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies’ profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research. Full disclaimer can be read at www.pennystockshark.com/disclaimer
I just don't get it...
This is so depressing. I am beating myself for not selling when it spiked after the news. I just don't understand stocks.
so we get the news everybody was looking for and the stock tanks. WTF! any ideas on if PIP is going to move? only been playing with stocks for a short time.
Am I seeing the screen right... It dropped to .16.
Hopefully, PIP will get some positive news reference the litigation, in the near future. Curious on how high the stock could go if the courts side with PIP.
check out IFSL. some solid news...
only .20 more and I am even :) Happy as hell to see ifsl with some life.
Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
http://quotes.stocknod.com/stocknod/?GUID=19244655&Page=MEDIAVIEWER
By: PharmAthene, Inc. via PRNewsWire News Releases
Posted on August 16, 2011 at 09:00 AM EDT
Flexible Manufacturing System Could Potentially Streamline Development Approach and Improve Cost Effectiveness
ANNAPOLIS, Md., Aug. 16, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company has been awarded a $5.7 million contract under a Department of Defense (DoD) Broad Agency Announcement for studies directed at the development of an advanced expression system for the bioproduction of its nerve agent medical countermeasure program.
rBChE is a recombinant form of a naturally occurring protein, human butyrylcholinesterase (BChE), which is found in minute quantities in blood. It functions as a natural bioscavenger, like a sponge, to absorb toxins such as organophosphorous poisons (nerve agents) and certain pesticides, before they cause irreversible neurological damage.
Preclinical studies in animals suggest rBChE has the potential to provide significant protection against chemical nerve agent poisoning when administered prophylactically (prior to exposure to nerve agent) and also may increase survival when administered therapeutically (following nerve agent exposure).
Funding under the new contract, which has a base period of 18 months, will be used to evaluate a novel mammalian cell-based manufacturing system for rBChE. If successful, this platform could potentially streamline the development approach for rBChE and increase the production yield, manufacturing flexibility, and cost-effectiveness of this program.
"We have considerable experience in the production and evaluation of recombinant BChE," remarked Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer. "This contract builds upon the body of knowledge we have established over the years with a specific focus on the expression of rBChE using a novel mammalian cell line that has been used for the advanced-stage bioproduction of other recombinant proteins with considerable FDA oversight and review."
Dr. Fuerst continued, "PharmAthene's commitment to innovation has enabled us to continue to develop and advance novel medical countermeasures, based on 21st century biopharmaceutical processes. These contracted studies will advance the state of the art of rBChE technology and, we believe, will position us to better meet the needs of our customer, the U. S. government. PharmAthene's approach is consistent with the government's initiative to support the use of flexible, state-of-the-art technologies to meet the needs of both the military and civilian strategic stockpiles. We are excited about the potential for a mammalian cell-based manufacturing system, which may yield improvements in a second generation product profile, and look forward to a productive collaboration with the DoD in the conduct of these studies that are key to the advancement of important new prophylactic and therapeutic medical countermeasures."
Man I can't believe what I am seeing. I have been in for approx. 2 years and basically wrote this one off. I am in for a shit load of money at .42. I guess you are not down and out until you sell. Go IFSL!!
So much for those articles that said this should be a $15 stock. WTF...
09:11 EDT PIP
theflyonthewall.com: PharmAthene data impressive, says Roth Capital
Roth Capital believes that recently announced data on PharmAthene's Sparvax is important and should be attractive to BARDA. The firm maintains a $4.50 and Buy rating on PharmAthene. :theflyonthewall.com
From stock nod.com. I am on my iPad and really dont know how to use.